The multi-institutional Montreal Cancer Consortium (MCC) comprises the Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), the Goodman Cancer Research Centre (GCRC), the Centre de Recherche de l’Hôpital Maisonneuve-Rosemont, the Institute for Research in Immunology and Cancer (IRIC), the Jewish General Hospital (JGH), the Génome Québec Innovation Centre, McGill University, the Université de Montréal, and the Research Institute of the McGill University Health Centre (RI-MUHC).
For the Terry Fox Research Institute, the launch of this consortium marks another step forward in their goal of accelerating precision medicine for all Canadians. The consortium is the second pilot project the Institute has created as part of its strategy to form a pan-Canadian network of linked cancer centres from coast to coast. The Montreal pilot project members will further develop a new cancer treatment strategy that enhances an individual’s immune system to fight cancer. This treatment, called immunotherapy, has recently shown impressive results for some patients.